 |
|
|
| |
Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Richard Barnard1; Jenny Anderson2; Daria Hazuda1; Sharon R Lewin2; Alyssa Martin4; Laura Martins5; Mauricio Montano3; Vicente Planelles5; Celsa Spina6 for the CARE Collaboratory7
1Merck Research Laboratories (West Point, PA), Merck & Co., Inc., Kenilworth, NJ, USA; 2The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; 3Gladstone Institute of Virology and Immunology, University of California, San Francisco, San Francisco, CA, USA; 4Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, and the Howard Hughes Medical Institute, Chevy Chase, MD, USA; 5Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA; 6Veterans Administration San Diego Healthcare System, San Diego, CA, USA, and Department of Pathology, University of California, San Diego, La Jolla, CA, USA; 7The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
|
| |
|
|
|
|
|
